$845K EBITDA Specialized Life Sciences R&D Firm in Pennsylvania

We have sourced a proprietary deal for a life sciences R&D firm in Pennsylvania. Below are the highlights: - 2025 Revenue: $6.8M - 2025 Adj. EBITDA: $0.8M - Team: 20 scientists/researchers (PhDs, etc.) - Technology: Early-stage drug discovery, medicinal chemistry (small molecule) - Owner Story: The Company is currently in a transition phase with the owners seeking retirement. Recent shifts in federal funding priorities have impacted a legacy revenue stream, creating a forecasted contraction for###-###-#### Secured Baseline: ~$3M–$4M). - Platform / Transition Opportunity: This is a unique Platform Opportunity. A strategic buyer can acquire a fully staffed, "turnkey" R&D facility with 20 expert scientists at a valuation based on forward secured flows rather than historical peak capability. If you would be interested in learning more, please select a time on our calendar for a brief, 15-minute intro call to discuss this deal. https://calendly.com/olive-stone/buyer-intro-call-15-minutes We charge a standard buy-side success fee at closing.